Numerion Labs

Numerion Labs is a United States-based drug discovery company headquartered in San Francisco, California. The company positions itself at the intersection of artificial intelligence and small-molecule drug hunting, describing its core technology as an "AI superplatform" that explores chemical space to discover novel, drug-like molecules. Its stated focus is on programs with first- and best-in-class potential in immune and inflammatory diseases. The company presents itself as a science- and engineering-driven organization, emphasizing a "world-class team of scientists and engineers" who are redefining how small-molecule drugs are discovered. Its public-facing messaging centers on the concept of "the art of drug hunting powered by ML," suggesting a workflow in which machine learning is used to search vast chemical libraries and generate candidate molecules that may not be found through conventional approaches. Numerion Labs operates in the highly competitive AI-driven drug discovery sector, where computational platforms are used to accelerate hit identification, lead optimization, and preclinical development. The company's therapeutic focus on immune and inflammatory diseases places it in a large and commercially significant area of biopharma R&D, spanning conditions such as autoimmune disorders and chronic inflammation. As of the available evidence, Numerion Labs is a private company. Its headquarters in San Francisco situates it within one of the world's densest biotechnology and technology ecosystems, providing access to talent, venture capital, and academic collaboration. The company maintains a public web presence at numerionlabs.ai, where it highlights its platform, its pipeline programs, and its team. Because the company appears to be relatively early-stage or privately held, detailed public information about its founding year, founders, investors, and specific pipeline assets is limited in the supplied evidence. The dossier below reflects only what can be supported by the available sources, with gaps left unfilled rather than guessed.

Numerion Labs is a privately held company headquartered in San Francisco, California, United States. Public evidence about its corporate history is limited. The company describes itself as operating at the forefront of machine-learning-enabled drug discovery, with a platform it calls an "AI superplatform" designed to explore chemical space and identify novel, drug-like molecules. The company's public messaging emphasizes three pillars: its platform, its programs, and its team. According to its website, the platform is used to discover molecules "unseen by others," while the programs it generates are intended to deliver first- and best-in-class potential in immune and inflammatory diseases. The company also highlights a "world-class team of scientists and engineers" working to redefine small-molecule drug discovery. Numerion Labs appears to be an early-stage or growth-stage biotechnology company. No founding date, founder names, funding rounds, or specific pipeline assets are provided in the available evidence. Its San Francisco location places it within a major hub for biotechnology, artificial intelligence, and venture capital, which is consistent with the profile of a computational drug discovery startup. The company maintains a website at numerionlabs.ai, which serves as its primary public communication channel. The site presents the company's tagline, "The Art of Drug Hunting • Powered by ML," and invites visitors to explore its platform, programs, and team. Because the available evidence is drawn primarily from the company's own website and a Wikidata entry identifying it as a company in San Francisco, this history remains necessarily brief. Further details about its corporate trajectory, partnerships, or financing would require additional sources.

AI-driven small-molecule drug discovery focused on immune and inflammatory diseases.

• AI superplatform

  A machine-learning platform that explores chemical space to discover novel, drug-like molecules.

• Immune and inflammatory disease programs

  Drug discovery programs generated by the AI superplatform, aimed at first- and best-in-class potential.

1. 1Innovative Approaches in Drug Discovery Using Machine Learningnumerionlabs.ai
2. 2Numerion Labs (United States) - Wikidatawikidata.org